COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
Description
CONCLUSIONS: RA with JAKi users had a significant risk for hospitalisation, mortality or composite adverse outcomes, especially higher mortality among those without COVID-19 vaccination. COVID-19 vaccination should be encouraged in these target
